| 发明名称 |
COMBINATION THERAPY FOR COPD |
| 摘要 |
Aerosol formulations comprising glycopyrronium chloride in combination with formoterol may be administered by means of a pressurized metered dose inhaler (pMDI) for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium chloride and the formoterol components. Optionally, the formulation may further comprise beclometasone dipropionate. |
| 申请公布号 |
US2014363384(A1) |
申请公布日期 |
2014.12.11 |
| 申请号 |
US201414467218 |
申请日期 |
2014.08.25 |
| 申请人 |
CHIESI FARMACEUTICI S.p.A. |
发明人 |
BONELLI Sauro;USBERTI Francesca;ZAMBELLI Enrico |
| 分类号 |
A61K47/06;A61M15/00;A61K31/573;A61K31/40;A61K31/136 |
主分类号 |
A61K47/06 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A pharmaceutical composition, comprising:
(a) glycopyrronium chloride; and (b) formoterol or a salt thereof; dissolved in an HFA propellant or a mixture of an HFA propellant with a co-solvent, to which composition has been added an amount of acid equivalent to 1M HCl in the range 0.1 to 0.3 μg/μl of the composition. |
| 地址 |
Parma IT |
